InHealth decodedbyInvitae® (a Labcorp company)Genetic testing helps one family navigate a challenging diagnosisWhen little Meaghen stopped meeting her developmental milestones, a genetic test helped her parents find better supportNov 21
InHealth decodedbyInvitae® (a Labcorp company)Genetic testing can improve care for people with neuromuscular diseasesNavigating neuromuscular diagnoses with genetic testing may lead to better treatmentJun 4
Research OutreachRare disease drug development: Time for a new approach?A limited patient population is a key challenge in rare disease drug development. Professor Shein-Chung Chow of Duke University School of…Oct 10Oct 10
InHealth decodedbyInvitae® (a Labcorp company)Finding Andrew’s truth: A family’s unexpected rare disease diagnosisFourteen years after Andrew’s first seizure, genetic testing finally offers him and his family an answer — and a path forward.Jan 16, 2023Jan 16, 2023
InRareativesbyJessica LynnMiplyffa’s Approval Ignites Hope for the Niemann-Pick Type C (NPC) CommunityThis drug approval has been years in the making.Oct 3Oct 3
InHealth decodedbyInvitae® (a Labcorp company)Genetic testing helps one family navigate a challenging diagnosisWhen little Meaghen stopped meeting her developmental milestones, a genetic test helped her parents find better supportNov 21
InHealth decodedbyInvitae® (a Labcorp company)Genetic testing can improve care for people with neuromuscular diseasesNavigating neuromuscular diagnoses with genetic testing may lead to better treatmentJun 4
Research OutreachRare disease drug development: Time for a new approach?A limited patient population is a key challenge in rare disease drug development. Professor Shein-Chung Chow of Duke University School of…Oct 10
InHealth decodedbyInvitae® (a Labcorp company)Finding Andrew’s truth: A family’s unexpected rare disease diagnosisFourteen years after Andrew’s first seizure, genetic testing finally offers him and his family an answer — and a path forward.Jan 16, 2023
InRareativesbyJessica LynnMiplyffa’s Approval Ignites Hope for the Niemann-Pick Type C (NPC) CommunityThis drug approval has been years in the making.Oct 3
Research OutreachBarth syndrome: A potential treatment for a rare diseaseBarth syndrome is a rare disorder in males caused by a variant of the gene TAFAZZIN. It affects the metabolism of the fat molecule…Aug 25
InHealth decodedbyInvitae® (a Labcorp company)“Just be Mom”: Leslie has the heart of a genetic counselorPatient advocacy defined: Leslie CyprychOct 19, 2023
InHealth decodedbyInvitae® (a Labcorp company)A patient-centered approach: The key to unlocking opportunities for novel rare disease treatmentsFor patients with pediatric epilepsy and/or developmental delay, Invitae’s Ciitizen platform helps accelerate new treatment optionsJan 9, 2023
